Outlook for Predictive Safety Technologies

CHI Advances Predictive Safety Survey --- September 2006 (n=46) Please classify you organization. 

1. Please specify your job title or function. 

2. Are you directly involved in the designing, planning, or conduct of safety assessments for discovery-stage or preclinical compounds? 

3. What type of agents are these primarily? 

4. Does your company employ in silico safety prediction tools (including outsourced work)? 

5. Do you typically conduct in vitro compound safety assessments prior to animal safety testing (including outsourced work)? 

6. Do you use high-content screening cell-culture or tissue-culture or organ-slice based as a decision support tool with respect to predictive safety assessments (including outsourced work)? 

7. Do you currently use or outsource one or more of the following predictive safety technologies: toxicogenomics, metabolic profiling, metabonomics? 

8. When will predictive safety assessments (using toxicogenomics, in silico technologies, metabonomics, etc.) become a routine part of preclinical safety testing at your organization? 

9. Do you believe that early-stage predictive safety assessments conducted prior to standard animal safety pharmacology will become mandatory components of an IND (or equivalent) at some time? 

10. Do you believe that extensive deployment of early-stage predictive safety assessments by drug developers could result in significant savings? 

11. Do you believe that widespread use of predictive safety technologies will result in fewer experimental animals being used? 

12. Would a globally standardized documentation and reporting format for the results of early-stage predictive safety assessments be useful? 

13. Do you expect major breakthroughs to occur with respect o novel predictive safety technologies through 2015?